https://www.selleckchem.com/pr....oducts/azeliragon.ht
Median BW was 139 kg, and 84% had body mass index (BMI) ≥ 40 kg/m . DOAC peak and trough concentrations varied from 44 to 727 and 14 to 299 ng/mL, respectively. There was no linear relationship between FXa inhibitor concentrations at peak or trough and BW or BMI, and creatinine clearance. Apixaban troughs in AF and rivaroxaban peaks in VTE were lower than in unselected populations. However, only two trough concentrations were below the expected range, and 109/116 were within the on-therapy range. These data indicated that obese or h
Like
Comment
Share
